Minerva Neurosciences, Inc.
NERV
NASDAQ·Healthcare·Biotechnology·Mkt cap $206.4M
$4.43
▼ -5.54%
P/E
—
Mkt Cap
$206.4M
52-Wk Range
$1.93–$12.46
52-Week Range
$1.93 - $12.46
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 104.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Novel mechanism of action with roluperidone offering differentiated schizophrenia treatment
- Global partnership with major pharmaceutical company Mitsubishi Tanabe Pharma
- Specialized expertise in central nervous system drug development
- Proprietary neuregulin-1b1 platform for neurodegenerative indications
Bear Case
1 risk
- Low volatility (beta -0.1).
Growth
Stable outlook
Clinical trial advancement and FDA approval pathway for roluperidone
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-10.7% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying NERV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 7, 2026
Reported EPS of -$0.14 vs -$0.19 consensus (+27.6% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+27.6%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Jefferies · Aug 14, 2026
vs Industry
How NERV stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.